RESISTENTIA INITIATES PHASE II CLINICAL TESTING OF NOVEL IMMUNOTHERAPEUTIC FOR ALLERGIC ASTHMA
April 22, 2007 – 8:05 pmResistentia Pharmaceuticals AB, a biopharmaceutical consort nonindustrial immunotherapeutic products for hypersensitised asthma and inflammatory disorders, declared today the advise of a Phase II clinical effort to appraise country and effectualness of a new anti-IgE immunotherapy, RP01, in hypersensitised individuals. RP01 is fashioned to rush the insusceptible grouping to display antibodies that country Immunoglobulin E (IgE), the key negotiator of an hypersensitised response.
The randomized, double-blind, placebo-controlled, multi-center, dose-escalation study, is existence conducted in New Zealand. The direct modify is country and tolerability of the immunotherapy. A sort of insusceptible markers module also be analysed as conception of an effectualness evaluation.
RP01 module be administered to apiece of threesome dosing groups in a sequential manner. This is to enable assessment of the country and tolerability of the prototypal shot before the next, higher pane is administered. The initial shot module be followed by threesome thief injections at the aforementioned dose. The think module terminal 52 weeks (with an interval psychotherapy at hebdomad 20) and allow 42 patients with an allergy towards at small digit aero allergen
"The advise of this effort is a momentous milestone, not exclusive in the utilization of RP01 but also for Resistentia as it is our advance therapeutic and prototypal to start Phase II," noted Marcus Bosson, CEO of Resistentia. "The results of the Phase I trials were rattling encouraging, specially the take of anti-IgE achieved in the volunteers unitedly with another markers of possibleness efficacy. Once replicated in the upcoming trials, RP01, with its new execution of action, could substance goodness to jillions of asthma and allergy patients. We countenance nervy to assessing interval accumulation from the think before the modify of 2007."
The Phase I effort of RP01 included individual groups of flourishing volunteers that were presented escalating doses. Data showed RP01 was innocuous and substantially tolerated. Participants also matured mensurable levels of anti-IgE antibodies, an primeval communication of possibleness efficacy. These accumulation based the selection to advise RP01 into Phase II clinical trials.
About Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals is a privately held biopharmaceutical consort nonindustrial original immunotherapies that direct hypersensitised asthma and hypersensitised redness as substantially as inflammatory disorders. In constituent to its advance anti-IgE immunotherapeutic, RP01, Resistentia has initiated pre-clinical utilization of an immunotherapeutic against hands bourgeois C5a for the communication of rheumatoid arthritis and another autoimmune diseases. Founded in1998, the consort has matured an industrialized methodicalness with skillfulness ranging from molecular immunology, pre-clinical and clinical take utilization to industrialized biopharmaceutical production. Major shareholders are HealthCap, Industrifonden, BankInvest, SR One and InnKap. Further aggregation crapper be institute at http://www.resistentia.se.
About RP01
RP01 is a new immunotherapeutic that stimulates the insusceptible grouping to display antibodies against immunoglobulin (Immunoglobulin E), the key negotiator of hypersensitised reactions. The antibodies grab and bond to IgE, thereby interference it from feat hypersensitised reactions. Such a execution of state is potentially trenchant disregarding of the trigger, be it pollen, grass, detritus mite, foodstuffs or pets. In Phase I trials, RP01 was safe, substantially tolerated and the flourishing volunteers matured momentous levels of anti-IgE antibodies. RP01 primarily targets patients with hypersensitised asthma still another forthcoming indications could allow hypersensitised redness and youngster allergy.